In spite of a setback, Praxis Precision Medicines, a Boston-based biotechnology company, plans to move its most advanced experimental drug into late-stage human testing.
On Friday, Praxis said its drug, named ulixacaltamide, failed to meet the main goal of a mid-stage clinical trial testing it as a treatment for essential tremor — a neurological disorder that causes involuntary shaking in the hands and arms and, sometimes, other parts of the body.
